Next Article in Journal
Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study
Previous Article in Journal
Composition and Function of Telomerase—A Polymerase Associated with the Origin of Eukaryotes
Article

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)

1
MODNBIO Inc., digital road 34, Kolon Science Valley I, Guro-gu, Seoul 08378, Korea
2
Department of Internal Medicine, Yonsei University College of Medicine, 50–1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
3
Institute of Biotechnology, Chungnam National University, Daejeon 34134, Korea
4
Cardiovascular Research Institute, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Biomolecules 2020, 10(10), 1426; https://doi.org/10.3390/biom10101426
Received: 1 September 2020 / Revised: 6 October 2020 / Accepted: 7 October 2020 / Published: 8 October 2020
Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but there have been few studies of gypenosides (Gyp). Particularly, no study on Gyp LXXV has been reported to date. Here, to firstly explore the pharmacological effects of Gyp LXXV against NASH and the related mechanism, methionine- and choline-deficient (MCD) diet-induced NASH mice and hepatic cells (stellate cells, hepatic macrophages, and hepatocytes) were selected. Gyp LXXV exhibited markedly alleviated MCD diet-induced hepatic injury, inflammation, and fibrosis by down-regulating hepatic fibrosis markers such as α-smooth muscle actin(α-SMA), collagen1, transforming growth factors-β (TGF-β1), tumor necrosis factor-α (TNF-α), MCP-1, interleukin (IL)-1β, nuclear factor κB (NFκB), and GRP78. Remarkably, histopathological studies confirmed that 15 mg/kg of Gyp LXXV administration to MCD diet-induced mice led to effective prevention of liver injury, lipid accumulation, and activation of hepatic macrophages, indicating that Gyp LXXV might be a potential anti-NASH drug. View Full-Text
Keywords: ginsenosides; gypenoside LXXV; drug discovery; liver fibrosis; nonalcoholic steatohepatitis (NASH); hepatic stellate cells ginsenosides; gypenoside LXXV; drug discovery; liver fibrosis; nonalcoholic steatohepatitis (NASH); hepatic stellate cells
Show Figures

Figure 1

MDPI and ACS Style

Lee, J.H.; Oh, J.Y.; Kim, S.H.; Oh, I.J.; Lee, Y.-h.; Lee, K.W.; Lee, W.H.; Kim, J.-H. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH). Biomolecules 2020, 10, 1426. https://doi.org/10.3390/biom10101426

AMA Style

Lee JH, Oh JY, Kim SH, Oh IJ, Lee Y-h, Lee KW, Lee WH, Kim J-H. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH). Biomolecules. 2020; 10(10):1426. https://doi.org/10.3390/biom10101426

Chicago/Turabian Style

Lee, Jin H., Ji Y. Oh, Soo H. Kim, In J. Oh, Yong-ho Lee, Keun W. Lee, Woong H. Lee, and Jeong-Hwan Kim. 2020. "Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)" Biomolecules 10, no. 10: 1426. https://doi.org/10.3390/biom10101426

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop